Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2549)	8/3/2009 4:26:14 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ALKS is up 8.04% on volume above 1,366,500 which is already > its ADV.<g> The stock has resistance at the $11.77 level from its H on Jul23 before it can test the $12 level and its March 26 H at $13.16 bigcharts.marketwatch.com The company is presenting on Wednesday at the BMO Capital Markets 9th Annual Focus on Healthcare Conference at the Millennium Broadway Hotel in New York City. And ob Thursday it has scheduled a C.C. after the market closes, to report and discuss its 1stQ results.<g> The consensus 'target' in Yahoo is $11.21, but it seems that with good news and the present better market environment it could get to test the $15 level.The Aug 2008 H was $17.04<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2549)	1/22/2010 12:26:04 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

SOMX has closed most of its January 2 DG.<g> The stock opened with a good UG and is still up 106% with volume > 19,955,700 close to 10x its ADV but still way below the 30.2M traded on Jan2 <g> bigcharts.marketwatch.com It provided yesterday an update on the status of its NDA of Silenor(doxepin) for the treatment of insomnia. SOMX said that it held a meeting with senior leadership at the FDA on Jan20 to discuss the issues raised by the FDA in Dec relating to the Silenor NDA. The only remaining efficacy issue was related to the robustness of sustained subjective sleep maintenance efficacy in non-elderly adults with primary insomnia. In the meeting on Wednesday, the FDA and SOMX discussed this issue, and the FDA instructed SOMX to resubmit the contents of its pre-meeting briefing package and it acknowledged that this resubmission would be considered a complete response to its letter in Dec.<g> The FDA also agreed that this would be considered a Class 1 resubmission with a two-month review cycle. No additional safety or efficacy data was required to be included in the resubmission, and the company filed the resubmission with the FDA yesterday. As a result, it anticipates a decision from the FDA by March 21. In the meeting the FDA also reiterated that a revised Risk Evaluation and Mitigation Strategy (REMS), including a Medication Guide to be distributed with the product, will be required. It seems that with some good news the stock could get back to the $5 level.<g> bigcharts.marketwatch.com Bernard